TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05260567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Lifestyle Change
Description: Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise and Lifestyle Change
Description: Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%.
Study: NCT05646953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Beauty Oil
Description: Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical
Study: NCT04774367

Intervention type: DEVICE
Group type: OTHER
Intervention: Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
Description: Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps

Intervention type: DEVICE
Group type: OTHER
Intervention: Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps
Description: Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
Study: NCT05850234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F (AZD0120)
Description: GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
Study: NCT05968469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercises with cycling ergometry
Description: A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit.
Study: NCT04467723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
Study: NCT06125392

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary physiology assessment
Description: Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
Study: NCT06465641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Methylphenidate hydrochloride in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose in capsules
Study: NCT06584383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exablate MRgFUS subthalamotomy
Description: Exablate MRgFUS subthalamotomy for Parkinson's Disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exablate MRgFUS subthalamotomy
Description: Exablate MRgFUS subthalamotomy for Parkinson's Disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
Study: NCT04940065

Intervention type: OTHER
Intervention: Kesimpta
Description: Prospective observational cohort study. There is no treatment allocation.
Study: NCT04173650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGLE 102
Description: Exosomes from MSCs up to six administrations
Study: NCT05445427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagal nerve stimulator
Description: Non-invasive vagus nerve stimulator
Study: NCT06481917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance care plan
Description: Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic analysis
Description: Ergonomic analysis throughout the intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of intervention acceptability
Description: Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
Study: NCT06529952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic surgery by resection and endocoagulation
Description: resection of lower edge, resection of upper edge and endocoagulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic surgery by endocoagulation only
Description: hysteroscopic endocoagulation to the base of the niche by roller ball

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormonal treatment
Description: using 3rd generation contraceptive pills
Study: NCT05157191

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT04260282

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab
Description: PCR for viruses and bacteria in nasal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab
Description: PCR for viruses and bacteria in nasal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Induced sputum microbiome
Description: Microbiome in induced sputum

Intervention type: DIAGNOSTIC_TEST
Intervention: Induced sputum microbiome
Description: Microbiome in induced sputum
Study: NCT03024593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health- and illness-related internet use
Study: NCT04994314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nCaF2 primer
Description: Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control primer
Description: Conventional orthodontic primer
Study: NCT04050163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MiSaver®
Description: Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MiSaver®
Description: Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MiSaver®
Description: Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
Study: NCT05718869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT05916417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS-fNIRS over the dl-PFC
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS-fNIRS over the dl-PFC
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.
Study: NCT05711355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Platelet-Rich Plasma after meningomyelocele sac repair
Description: Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: meningomyelocele sac repair
Description: meningomyelocele sac repair without Platelet-Rich Plasma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: meningomyelocele sac repair
Description: meningomyelocele sac repair without Platelet-Rich Plasma
Study: NCT04941651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OBE-COACH program
Description: OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program.~The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses.~To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals.~The intensity level of the program is selected by the user at any time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected devices
Description: Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Connected devices
Description: Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Activity Tracer
Description: The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Connected Activity Tracer
Description: The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-learning program
Description: e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
Study: NCT06468059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Layered Low Profile Foot
Description: The layered LPF is a novel low-profile prosthetic foot that provides compliant behavior while simultaneously exhibiting high mechanical strength.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Layered Low Profile Foot
Description: The layered LPF is a novel low-profile prosthetic foot that provides compliant behavior while simultaneously exhibiting high mechanical strength.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prescribed Ankle
Description: The prescribed ankle is the prosthetic ankle that the subject wears for daily use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prescribed Ankle
Description: The prescribed ankle is the prosthetic ankle that the subject wears for daily use.
Study: NCT06382701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: Patients in the intervention group; ten minutes before the needle is inserted into the arterio-venous fistula, clove oil will be applied by the interviewer as a spray between 0.5-1 ml, depending on the length of the patient's fistula. Patients in the placebo group; 10 minutes before the needle is inserted into the arterio-venous fistula, 0.5-1 ml of aromatic cloves, which do not contain active ingredients and dissolved in pure water, will be applied as a spray by the interviewer, depending on the length of the patient's fistula.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This is the group in which 0.5-1 ml of aromatic clove, which does not contain active ingredients and is dissolved in pure water, is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
Study: NCT04973267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Plan for PrEP
Description: See arm description.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention-Matched Control Lifestyle Habits Videos
Description: Web-based videos providing information on sleep hygiene and proper diet.
Study: NCT05868330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Catheter
Description: Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exparel Single Shot Interscalene Block
Description: Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
Study: NCT05154669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial counseling
Description: The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Agent - Patches
Description: 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Agent - Patches
Description: 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Agent - Lozenges
Description: General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated
Study: NCT05499429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial low intensity focused ultrasound stimulation
Description: Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
Study: NCT05154669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Agent - Lozenges
Description: General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Agent - Gum
Description: Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Agent - Gum
Description: Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
Study: NCT05783167

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-sampling for HPV infection
Description: After informed consent has been provided, the woman will be asked to collect firstly a first-void urine sample using the Collipee device and secondly to collect a vaginal self-sample using the dry Evalyn® Brush device. Socioeconomic, demographic and clinical data will be collected in the Bissau HIV Cohort database and through study questionnaires to collect background information on risk factors for HPV persistence and development of cervical cancer (HIV genotype, immune status, parity). Questionnaires will collect additional information on the acceptance of cervical screening measures to better evaluate the feasibility of implementing self-collected screening among HIV infected women in Guinea-Bissau.
Study: NCT05163925

Intervention type: DEVICE
Intervention: Eurosets ECMO Life System
Description: ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab).
Study: NCT06455553

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A blood sample will be taken from all patients included in the study. This blood sampling is an added act of the study. It will be performed as soon as possible after inclusion in the study. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.